GAPDHP72: A Potential Drug Target and Biomarker (G346085)

Target Name: GAPDHP72

NCBI ID: G346085

GAPDHP72

Other Name(s): glyceraldehyde-3-phosphate dehydrogenase pseudogene 72 | GAPDL18 | Glyceraldehyde-3-phosphate dehydrogenase-like 18, pseudogene | GAPDHL18 | Glyceraldehyde-3-phosphate dehydrogenase pseudogene 72

GAPDHP72: A Potential Drug Target and Biomarker

Glyceraldehyde-3-phosphate dehydrogenase (GAPDHP) is a key enzyme in the glycolytic pathway, which is a critical pathway for cellular energy metabolism. GAPDHP is involved in the catalytic reaction of the first step of the glycolytic pathway, which is the conversion of glucose into pyruvate. The GAPDHP enzyme is composed of two subunits, alpha and beta subunits, which are located on the cytoplasmic side of the cell membrane. GAPDHP is a pseudogene, which means that it is a genetic copy of a gene that is not expressed in the cell.

GAPDHP has been identified as a potential drug target and biomarker for several reasons. Firstly, GAPDHP is a key enzyme in the glycolytic pathway, which is a critical pathway for cellular energy metabolism. GAPDHP is involved in the catalytic reaction of the first step of the glycolytic pathway, which is the conversion of glucose into pyruvate. Therefore, inhibiting the activity of GAPDHP could potentially lead to a decrease in the rate of glucose metabolism and provide an therapeutic target for diseases associated with altered glucose metabolism, such as diabetes.

Secondly, GAPDHP is a pseudogene, which means that it is a genetic copy of a gene that is not expressed in the cell. Therefore, it is possible that inhibiting the activity of GAPDHP could lead to unintended effects on other genes in the cell, which could potentially increase the risk of toxic effects. However, this is a potential drawback that needs to be further studied to determine if it is a real concern.

Thirdly, GAPDHP has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, GAPDHP has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, GAPDHP has also been shown to be involved in the development and progression of cancer, by promoting the growth and survival of cancer cells. Therefore, targeting GAPDHP with drugs or other therapeutic agents could potentially lead to a reduction in the risk of disease progression.

Finally, GAPDHP has been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. Therefore, targeting GAPDHP with drugs or other therapeutic agents could potentially lead to a reduction in the ability of cancer cells to spread and promote the growth and survival of cancer cells.

In conclusion, GAPDHP is a potential drug target and biomarker for several reasons. Firstly, GAPDHP is a key enzyme in the glycolytic pathway, which is a critical pathway for cellular energy metabolism. Secondly, GAPDHP is a pseudogene, which means that it is a genetic copy of a gene that is not expressed in the cell. Thirdly, GAPDHP has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Finally, GAPDHP has also been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. Therefore, targeting GAPDHP with drugs or other therapeutic agents could potentially lead to a reduction in the risk of disease progression and improve treatment outcomes. Further research is needed to determine if targeting GAPDHP is a viable therapeutic approach for the treatment of these diseases.

Protein Name: Glyceraldehyde-3-phosphate Dehydrogenase Pseudogene 72

The "GAPDHP72 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GAPDHP72 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets